Contineum Therapeutics (CTNM) vs REGENXBIO (RGNX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Contineum Therapeutics (CTNM) has outperformed REGENXBIO (RGNX) over the past year, gaining 10.0% versus a loss of 33.8%. REGENXBIO is the larger company by market cap ($532.7 million vs $503.4 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CTNM | RGNX |
|---|---|---|
| Share price | $13.38 | $8.07 |
| Market cap | $503.37M | $532.73M |
| 1-day change | +1.52% | -0.25% |
| YTD return | +17.06% | -43.82% |
| 1-year return | +10.03% | -33.80% |
| 5-year return | — | -77.50% |
| EPS (TTM) | $-1.73 | $-3.77 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $17.79 | $16.19 |
| 52-week low | $8.60 | $5.46 |
| Distance from 52-week high | -24.77% | -50.15% |
| Analyst consensus | strong_buy | buy |
| Avg. price target upside | +67.64% | +192.19% |
| Average volume | 520.62K | 1.50M |
| Shares outstanding | 32.96M | 66.01M |
| Employees | 51 | 371 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- CTNM has outperformed RGNX by 43.8 percentage points over the past year.
About Contineum Therapeutics
CTNM stock →Contineum Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing of small molecules different therapies for neuroscience, inflammation, and immunology indications in the United States. The company's lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and chronic pain.
Health Care · Biotechnology: Pharmaceutical Preparations · 51 employees
About REGENXBIO
RGNX stock →REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 371 employees
CTNM vs RGNX FAQ
Which is bigger, Contineum Therapeutics or REGENXBIO?
REGENXBIO (RGNX) is larger, with a market capitalization of $532.73M compared with $503.37M for Contineum Therapeutics (CTNM).
Which stock has performed better over the past year, CTNM or RGNX?
CTNM returned +10.03% over the past 12 months, compared with -33.80% for RGNX (price return, excluding dividends). Past performance does not predict future results.
Are Contineum Therapeutics and REGENXBIO in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Pharmaceutical Preparations for Contineum Therapeutics and Biotechnology: Biological Products (No Diagnostic Substances) for REGENXBIO.